On Oct. 22, 2020, Oxford Immunotec announced that it had been selected to provide T cell testing to the UK Vaccines Taskforce, a body formed by the UK Government to assess the suitability of vaccines for use in the UK population.

Oxford Immunotec was chosen in a competitive process for its expertise in T cell measurement and its unique ability to provide T-SPOT technology, the only globally regulated ELISPOT platform, currently used clinically for identifying T cells made in response to another respiratory pathogen responsible for Tuberculosis.